ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "H.E.G.1’s Role in Blood Pressure Control Revealed 09/24/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded September 24, 2025. This episode summarizes 5 key cardiology studies on topics like blood pressure and geographic variation. Key takeaway: H.E.G.1’s Role in Blood Pressure Control Revealed.
Article Links:
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure. (European heart journal)
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. (European heart journal)
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve. (Cardiovascular research)
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF. (ESC heart failure)
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/
Featured Articles
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40986512
Summary: This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985963
Summary: This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985755
Summary: This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40983954
Summary: This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40977249
Summary: This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.
Transcript
Today’s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Shear stress-induced endothelial H.E.G.1 signalling regulates vascular tone and blood pressure. This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.
Article number two. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.
Article number three. Invasive validation of novel 1D models for computation of coronary fractional flow reserve. This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.
Article number four. Finerenone in diabetic chronic kidney disease-Real-world insights including patients with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.
Article number five. Geographic region variation in patient characteristics, clinical outcomes and treatment of Heart Failure with Reduced Ejection Fraction in the VICTORIA trial. This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.
Thank you for listening. Don’t forget to subscribe.
Keywords
blood pressure, geographic variation, transcriptomic biomarkers, Heart Failure with Preserved Ejection Fraction, fractional flow reserve, endothelial cells, shear stress, finerenone, one-dimensional models, Heart development protein with epidermal growth factor-like domain 1, heart-directed radiotherapy, mineralocorticoid receptor antagonist, anthracyclines, guideline-directed medical therapy, vasodilation, coronary artery disease, clinical outcomes, vericiguat, Heart Failure with Reduced Ejection Fraction, type 2 diabetes mellitus, chronic kidney disease, cardiac disease, angiography, childhood cancer survivors, virtual fractional flow reserve.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post H.E.G.1’s Role in Blood Pressure Control Revealed 09/24/25 first appeared on Cardiology Today.
Article Links:
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure. (European heart journal)
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. (European heart journal)
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve. (Cardiovascular research)
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF. (ESC heart failure)
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial. (ESC heart failure)
Full episode page: https://podcast.explainheart.com/podcast/h-e-g-1s-role-in-blood-pressure-control-revealed-09-24-25/
Featured Articles
Article 1: Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40986512
Summary: This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.
Article 2: Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985963
Summary: This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.
Article 3: Invasive validation of novel 1D models for computation of coronary fractional flow reserve.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40985755
Summary: This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.
Article 4: Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40983954
Summary: This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.
Article 5: Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40977249
Summary: This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.
Transcript
Today’s date is September 24, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Shear stress-induced endothelial H.E.G.1 signalling regulates vascular tone and blood pressure. This study demonstrates that Heart development protein with epidermal growth factor-like domain 1, or H.E.G.1., in endothelial cells is critical for sensing shear stress and regulating vasodilation, directly impacting systemic blood pressure. Phenome-wide association studies showed a strong inverse relationship between endothelial H.E.G.1 levels and cardiovascular risk factors, suggesting that impaired H.E.G.1 function contributes to endothelial dysfunction and hypertension. These findings highlight H.E.G.1 as a potential therapeutic target for managing blood pressure and preventing cardiovascular disease.
Article number two. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. This case-control study identified transcriptomic biomarkers associated with cardiac disease in childhood cancer survivors, comparing gene expression in 165 survivors with cardiac disease to 165 cardiac disease-free controls. Specific genes were found to be differentially expressed in survivors who developed cardiac complications after cardiotoxic cancer treatments like anthracyclines and heart-directed radiotherapy. The identified biomarkers may help predict and personalize treatment strategies to mitigate cardiac risks in this vulnerable population.
Article number three. Invasive validation of novel 1D models for computation of coronary fractional flow reserve. This study assessed the accuracy of five one-dimensional virtual fractional flow reserve, or v.F.F.R., models against invasively measured fractional flow reserve, or F.F.R., for assessing coronary lesions. The one-dimensional models, which incorporate side-branch flow representation, significantly reduce simulation time compared to three-dimensional alternatives. Results showed good agreement and diagnostic accuracy compared to established F.F.R. methods, suggesting that one-dimensional v.F.F.R. models can provide a faster and reliable non-invasive tool for evaluating coronary artery disease.
Article number four. Finerenone in diabetic chronic kidney disease-Real-world insights including patients with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. This study examined the real-world safety and cardiac effects of finerenone in patients with chronic kidney disease and type 2 diabetes, including those with Heart Failure with Preserved Ejection Fraction or Heart Failure with Mid-Range Ejection Fraction. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a reduction in heart failure events and cardiovascular death. The study provides evidence supporting the use of finerenone to improve cardiac outcomes in this high-risk patient population.
Article number five. Geographic region variation in patient characteristics, clinical outcomes and treatment of Heart Failure with Reduced Ejection Fraction in the VICTORIA trial. This analysis of the VICTORIA trial investigates how geographic variations impact patient characteristics, guideline-directed medical therapy, and clinical outcomes in individuals with Heart Failure with Reduced Ejection Fraction. The study evaluated the influence of regional differences on the effectiveness of vericiguat compared to placebo. The findings underscore the need to consider geographic factors when tailoring heart failure management strategies to optimize patient care and outcomes.
Thank you for listening. Don’t forget to subscribe.
Keywords
blood pressure, geographic variation, transcriptomic biomarkers, Heart Failure with Preserved Ejection Fraction, fractional flow reserve, endothelial cells, shear stress, finerenone, one-dimensional models, Heart development protein with epidermal growth factor-like domain 1, heart-directed radiotherapy, mineralocorticoid receptor antagonist, anthracyclines, guideline-directed medical therapy, vasodilation, coronary artery disease, clinical outcomes, vericiguat, Heart Failure with Reduced Ejection Fraction, type 2 diabetes mellitus, chronic kidney disease, cardiac disease, angiography, childhood cancer survivors, virtual fractional flow reserve.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post H.E.G.1’s Role in Blood Pressure Control Revealed 09/24/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust